Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Arch Biopartners Inc V.ARCH

Alternate Symbol(s):  ACHFF

Arch Biopartners Inc. is a late-stage clinical trial company focused on preventing acute kidney injury. The Company is developing a platform of new drugs to prevent inflammation injury in the kidneys, lungs and liver via the dipeptidase-1 (DPEP1) pathway and are relevant for many common injuries and diseases where organ inflammation is an unmet problem. The Company’s lead drug candidate is LSALT Peptide. The Company is engaged in the clinical development of LSALT Peptide and other DPEP-1 targeting drug candidates for indications where inflammation of the lungs, liver and kidneys is an unmet problem. LSALT Peptide is in a second phase II trial, targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI). The Company has additional technology platforms in its portfolio, which are AB569 and Borg. AB569 is an anti-infective candidate for treating or preventing antibiotic resistant bacterial infections, primarily as a topical treatment for wounds.


TSXV:ARCH - Post by User

Post by Viking2233on Jun 27, 2023 5:32pm
126 Views
Post# 35517243

Wild Ride Today

Wild Ride TodayWell I told everybody to buckle up and you sure beeded your seat belt today. $2:14 to $2.38 in the first hour then the shorts stepped back in and quickly knocked in back down to $2.18. We slowly recovered to close at $2.30 on volume of 150K on TSXV.

Todays news should further convince those on the sidelines that we have now had phase 2 data reviewed and supported by Health Canada and FDA. The fact we are now approved by FDA for new phase 2 trial along with $5M of Government of Canada funding which eliminates any need to raise further funds that would normally cause dilution plus we successfully completed a increased dose study and the new phase 2 trial for AKI could also open the door to fast tracking do to the fact there are no approved treatments for AKI.

The sky is looking brighter but in all fairness I personally felt todays news release should have drove us back up to the $4-5 dollar range.

We still are waiting for third party independent phase data review. This is key catalyst for the Raymond James Analyst to bump up his target price and hopefully move from speculative buy to a strong buy. I personally feel the news today (FDA) + successful increased dosage study+ $5M Government Funding with no dilution+ 3rd Party Independent Review Study should move us up to where our similar staged perrs are valued in the $800M to $1.5B market cap.

We need to get real buying interest to move this up with conviction to convince the shorts to cover. I liked the action today especially the fact we recovered from the $2.18 short attack to end up 7.5%. We need to get off the Venture to bring in bug money but we need share price up to do that!
<< Previous
Bullboard Posts
Next >>